Prosecution Insights
Prosecution Insights
20 pending office actions • 16 art units • 19 examiners • 0 of 20 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 9 (45%) |
| §102 only | 3 (15%) |
| §112 only | 2 (10%) |
| Double-patenting only | 5 (25%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG, KAIJIANG | 2 | 76.8% | +34.8% |
| HILL, KEVIN KAI | 1 | 36.1% | +33.4% |
| REDDIG, PETER J | 1 | 58.0% | +40.1% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 100.0% | +0.0% |
| WANG, RUIXUE | 1 | 56.2% | +25.7% |
| SIFFORD, JEFFREY MARK | 1 | 57.0% | +33.7% |
| ROGERS, ERIC JASON | 1 | 57.8% | +30.0% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| KOVACH, KARA NICOLE | 1 | 85.7% | +100.0% |
| JUEDES, AMY E | 1 | 44.7% | +41.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18340699 | INFERRING TRANSCRIPTION FACTOR ACTIVITY FROM DNA METHYLATION AND ITS APPLICATION AS A BIOMARKER | KOVACH, KARA NICOLE | 16d overdue |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458108 | EPSTEIN BARR VIRUS VACCINES | WANG, RUIXUE | 49d overdue |
| 18340699 | INFERRING TRANSCRIPTION FACTOR ACTIVITY FROM DNA METHYLATION AND ITS APPLICATION AS A BIOMARKER | KOVACH, KARA NICOLE | 16d overdue |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 5d |
| 17464341 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 65d |
| 19031042 | METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY | HILL, KEVIN KAI | — |
| 18548017 | PROTECTIVE ANTIBODIES AGAINST RESPIRATORY VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | — |
| 18262674 | TREATMENT FOR HSV-1 USING A MEGANUCLEASE | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1684 | 3 |
| 1638 | 2 |
| 1672 | 2 |
| 1646 | 1 |
| 1671 | 1 |
| 1642 | 1 |
| 1681 | 1 |
| 1644 | 1 |
| 1674 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19031042 | METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY | HILL, KEVIN KAI | 1638 | §103 | Final Rejection | — | Pending | Jan 17, 2025 |
| 18500706 | COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS | REDDIG, PETER J | 1646 | Other | Non-Final OA | 5d | Pending | Nov 02, 2023 |
| 18557406 | MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18458108 | EPSTEIN BARR VIRUS VACCINES | WANG, RUIXUE | 1672 | §112 | Non-Final OA | 49d overdue | Pending | Aug 29, 2023 |
| 18548017 | PROTECTIVE ANTIBODIES AGAINST RESPIRATORY VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | 1671 | DP | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18262674 | TREATMENT FOR HSV-1 USING A MEGANUCLEASE | ROGERS, ERIC JASON | 1638 | DP | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18350637 | IGM-MULTIMERIZED SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 | PRIEST, JESSICA MARIE | 1642 | DP | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18340699 | INFERRING TRANSCRIPTION FACTOR ACTIVITY FROM DNA METHYLATION AND ITS APPLICATION AS A BIOMARKER | KOVACH, KARA NICOLE | 1681 | §103 | Non-Final OA | 16d overdue | Pending | Jun 23, 2023 |
| 18257814 | IMMUNOGENIC COMPOSITIONS | JUEDES, AMY E | 1644 | DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | HOWARD, ZACHARY C | 1674 | §103 | Final Rejection | — | Pending | May 04, 2023 |
| 18249149 | SPECIFIC TARGETING OF TUMOR-INFILTRATING REGULATORY T CELLS (TREGS) USING ICOS AND IL-1R | CHATTIN, AMY MARIE | 1643 | §103 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18044289 | IMPROVED HIGH EFFICIENCY TARGETED IN SITU GENOME-WIDE PROFILING | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Final Rejection | — | Pending | Mar 07, 2023 |
| 18063532 | METHODS AND MATERIALS FOR CANINE BREED IDENTIFICATION | WHALEY, PABLO S | 3619 | §112 | Final Rejection | 7d | Pending | Dec 08, 2022 |
| 17999240 | ANTI-FIBROTIC COMPOSITION AND RELATED METHODS | KOSTURKO, GEORGE W | 1621 | §103 | Non-Final OA | 26d | Pending | Nov 18, 2022 |
| 17631399 | METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROENVIRONMENTS | YU, MISOOK | 1641 | §102 | Final Rejection | 73d overdue | Pending | Jan 28, 2022 |
| 17464341 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §102 | Non-Final OA | 65d | Pending | Sep 01, 2021 |
| 17412105 | COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS | ZHANG, KAIJIANG | 1684 | §102 | Non-Final OA | 65d | Pending | Aug 25, 2021 |
| 17312703 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FISCHER, JOSEPH | 1658 | DP | Final Rejection | — | Pending | Jun 10, 2021 |
| 17044779 | NANOPARTICLES FOR GENE EXPRESSION AND USES THEREOF | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Non-Final OA | 46d overdue | Pending | Oct 01, 2020 |
| 17029756 | CELL POPULATION ANALYSIS USING SINGLE NUCLEOTIDE POLYMORPHISMS FROM SINGLE CELL TRANSCRIPTOMES | PARISI, JESSICA DANIELLE | 1684 | §103 | Final Rejection | — | Pending | Sep 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial